Yukinori Okada MD, Presenter: Nothing to Disclose

Yasuo Nakajima MD, Abstract Co-Author: Nothing to Disclose

Itsuko Okuda MD, Abstract Co-Author: Nothing to Disclose

Yasuyuki Kojima, Abstract Co-Author: Nothing to Disclose

Artificial neural network-based bone scan index (BSI) has been used to quantify the spread of bone metastasis. Currently, BSI has been used as a prognostic indicator in prostate cancer. However, the utility of BSI in breast cancer patients who has bone metastasis is not clear. To elucidate the role of BSI in breast cancer patients with bone metastasis used zoledronic acid, we examined the relationship between BSI, their tumor maker and survival.

Fifty-four female patients, ranging from 32 to 78 years of age with average of 54.4 years old, were treated for bone metastasis of breast cancer between 1 January 2006 and 27 October 2012. Bone scintigraphies were analyzed using BONE NAVI version 1 (FUJIFILMRI pharma, Co. Ltd. Tokyo Japan; EXINI BoneExini Diagnostics, Sweden) and BSI were calculated at the time whose bone metastasis were found, and the time after  6 months (range 3 months to 9 months) and 12 months (range10 months to 17 months). At the same time, the serum marker of CA15-3 (51 patients) or CEA (49 patients) were examined. Survival rates were compared with BSI and tumor makers using the Kaplan-Meier method.

Survival was significantly better in patients with a BSI change rate ≤1 after  6 months and  12 months than in patients with a BSI change rate >1 after 6 months and 12 monthes (6 months, p=0.028; 12 months, p=0.005). Survival was significantly better in patients with a tumor marker change rate ≤1 after 12 months than in patients with a tumor marker change rate >1 after 12 months (CA15-3; p=0.041, CEA; p=0.048), but there were no significant intergroup differences of there survival between patients with a tumor marker change rate ≤1 and a tumor marker change rate >1 after 6 months (CA15-3; p=0.507, CEA; p=0.585). There were no significant intergroup differences between patients with a BSI ≤ median　and BSI > median (median; 0.67, p=0.67), with a BSI ≤ mean and BSI > mean (mean; 1.414, p=0.421).

The BSI change rate after 6 months and after 12 months, and the tumor marker change rate after12 months after onset of bone metastasis are a prognostic factor in breast cancer patients with bone metastasis. The BSI  can predict patient`s prognosis earlier than tumor makers.

The BSI change is a useful prognositc factor in breast cancer patients with bone metastasis.

Okada, Y, Nakajima, Y, Okuda, I, Kojima, Y, The Bone Scan Index (BSI) Is a Prognostic Factor in Breast Cancer Patients with Bone Metastasis Treated with Zoledronic Acid.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14010439.html